Cohance Lifesciences announces $10 M investment in cGMP Bioconjugation Suite in US

CAR-T Digest - August 2020

12 August 2025: Cohance Lifesciences announces $10 M investment in cGMP Bioconjugation Suite in US

Cohance Lifesciences is investing $10 million to expand cGMP bioconjugation capabilities at its US-based subsidiary, NJ Bio, to strengthen its position in the Antibody-Drug Conjugate (ADC) space
The investment will enable the construction of a state-of-the-art bioconjugation suite in Princeton, New Jersey, offering end-to-end ADC manufacturing services from early-phase development to clinical supply
NJ Bio is already working on a major ADC program for an existing customer, progressing from payload-linker development to cGMP bioconjugation, demonstrating its capacity for complex chemistry solutions
The new suite will be capable of producing up to 2 kg of ADCs for clinical use and is expected to be operational by the end of Q4FY26
NJ Bio is in advanced talks with additional customers and has recently expanded its linker-payload lab capabilities, reflecting strong momentum in the growing global ADC market